Baker Avenue Asset Management, LP Neurocrine Biosciences Inc Transaction History

Baker Avenue Asset Management, LP

  • $3.41 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$94.02 - $117.1 $5,171 - $6,440
55 Added 423.08%
68 $7,000
Q2 2023

Aug 11, 2023
SELL
$89.53 - $104.87 $268 - $314
-3 Reduced 18.75%
13 $1,000
Q1 2023

May 15, 2023
SELL
$94.11 - $123.02 $1,411 - $1,845
-15 Reduced 48.39%
16 $1,000
Q4 2022

Feb 13, 2023
BUY
$106.72 - $127.06 $3,308 - $3,938
31 New
31 $3,000

Others Institutions Holding NBIX

# of Institutions
635
Shares Held
93.5M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $14.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Baker Avenue Asset Management, LP Portfolio

Follow Baker Avenue Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Avenue Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email